Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sikarin PCLBKK:SKR-R -0.63%90 EV-to-EBIT is 19.31 as of Aug. 26, 2026, which is 24% below its 10-year median of 25.40. GuruFocus rates BKK:SKR-R with a GF Score™ of 90/100 and a GF Value™ of ฿8.11 (Fairly Valued). The stock has 5 warning signs investors should review. Among 479 Healthcare Providers & Services companies, Sikarin PCL ranks worse than 61.8% on this metric.
The historical rank and industry rank for Sikarin PCL's EV-to-EBIT or its related term are showing as below:
BKK:SKR-R'
s EV-to-EBIT Range Over the Past 10 Years
Min: 11.33 Med: 25.4 Max: 42.59
Current: 19.31
During the past 13 years, the highest EV-to-EBIT of Sikarin PCL was 42.59. The lowest was 11.33. And the median was 25.40.
BKK:SKR-R's EV-to-EBIT is ranked worse than 61.8% of 479
companies
in the Healthcare Providers & Services industry
Industry Median: 15.7
vs BKK:SKR-R: 19.31
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Sikarin PCL's Enterprise Value for the quarter that ended in Jun. 2026 was ฿13,412 Mil.
Sikarin PCL's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ฿798 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sikarin PCL EV-to-EBIT Related Terms
Sikarin PCL EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Sikarin PCL's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Care Facilities subindustry, Sikarin PCL's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sikarin PCL EV-to-EBIT vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Sikarin PCL's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Sikarin PCL's EV-to-EBIT falls into.
Sikarin PCL's current Enterprise Value is ฿15,408 Mil.
Sikarin PCL's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ฿798 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sikarin PCL (BKK:SKR-R) has a EV-to-EBIT of 19.31 as of Aug. 26, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Sikarin PCL and its competitors. This is 24% below median its historical median of 25.40. Over the past decade, Sikarin PCL's EV-to-EBIT has ranged from 11.33 to 42.59. According to the industry distribution chart, Sikarin PCL ranks #296 out of 479 companies in the Healthcare Providers & Services industry, placing it in the top 61.8%.
Is Sikarin PCL's EV-to-EBIT too high?
Sikarin PCL's current EV-to-EBIT of 19.31 is 24% below median its 10-year median of 25.40. Over the past 10 years, this metric has ranged from a low of 11.33 to a high of 42.59. The Healthcare Providers & Services industry median EV-to-EBIT is 15.70. Sikarin PCL's value of 19.31 is 23% above this industry median. Based on the distribution chart, Sikarin PCL ranks #296 out of 479 companies in the Healthcare Providers & Services industry, which is below the industry midpoint. Overall, Sikarin PCL has a GF Score™ of 90/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Sikarin PCL's EV-to-EBIT compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, Sikarin PCL ranks #296 out of 479 companies for EV-to-EBIT. This places Sikarin PCL in the lower half of its industry. The industry median EV-to-EBIT is 15.70. Sikarin PCL's value of 19.31 is 23% above this benchmark. Historically, Sikarin PCL's own EV-to-EBIT has ranged from 11.33 to 42.59 over the past decade. While the company's 10-year median is 25.40 vs. the industry median of 15.70, Sikarin PCL has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Healthcare Providers & Services company?
The median EV-to-EBIT among Healthcare Providers & Services companies is 15.70, based on 479 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sikarin PCL's current EV-to-EBIT of 19.31 is 23% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Sikarin PCL and its competitors. For the Healthcare Providers & Services industry, the median EV-to-EBIT is 15.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sikarin PCL's current EV-to-EBIT is 19.31, which is 24% below median its own 10-year median of 25.40. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sikarin PCL stock overvalued right now?
Based on GuruFocus' analysis, Sikarin PCL (BKK:SKR-R) is currently considered Fairly Valued. The stock's GF Value™ is ฿8.11, compared to a current price of ฿7.85 — trading 3.2% below its estimated fair value. The current EV-to-EBIT is 19.31, which is 24% below median its 10-year median of 25.40 and 23% above the Healthcare Providers & Services industry median of 15.70. Sikarin PCL's overall GF Score™ is 90/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Sikarin PCL (BKK:SKR-R), the current EV-to-EBIT is 19.31 as of Aug. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sikarin PCL (BKK:SKR-R) Overvalued in 2026?
Based on GuruFocus' analysis, Sikarin PCL stock appears to be undervalued.
The current stock price of ฿7.85 is trading 3.2% below its estimated GF Value™ of ฿8.11.
GuruFocus considers Sikarin PCL to be Fairly Valued.
Key valuation signals for BKK:SKR-R:
EV-to-EBIT: 19.31 (24% below median its 10-year median of 25.40)
GF Value™: ฿8.11 vs. price of ฿7.85 (3.2% below fair value)
Industry Position: 23% above the Healthcare Providers & Services median (#296 of 479)
No single metric tells the full story. See the BKK:SKR-R stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
SSikarin PCL provides general healthcare services and operates under the social security system. The Group has one main operating segment, which is providing healthcare services through private hospitals and hospitals affiliated with the social security system. The Group operates in a single geographical area, which is Thailand. Its services include medical centers, a pediatric center, a women's institute, a radiology center, a neurology center, a rehabilitation center, and an orthopedic center.
90GF Score
Get the complete analysis for BKK:SKR-R
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BKK:SKR-R has been successfully added to your 
